NCT05761509View on ClinicalTrials.gov

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"

CompletedOBSERVATIONAL

Enrollment

226

Participants

Timeline

Start Date

June 8, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

HIV Infections

Interventions

DRUG

Doravirine

The study treatments will used during 28 days according to the routine care of each investigator center.

Trial Locations (3)

34295

Service de maladies infectieuses et tropicales du CHU de Montpellier, Montpellier

75012

Hopital Saint Antoine, Paris

75013

Service de maladies infectieuses et tropicales de de l'hôpital La Pitié-Salpêtrière, Paris

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

OTHER

NCT05761509 - "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" | Biotech Hunter | Biotech Hunter